Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 02, 2022 4:43pm
246 Views
Post# 35067822

RE: I wonder what that portends after we get through the ...?

RE: I wonder what that portends after we get through the ...?stuckcatinthetree

I never made a $ 8 prediction* for the Spectral share price (at least not for the short term).

I did mention .68 last year in 2021, predicated on an enrolment uptick and some fanfare around trial partners and distribtuion partners - neither of which admittedly has materialized in a big way...YET !

Alas we only hit .61 earlier this year (for BSW's benefit, I missed by a few months - sorry. You and he can go ahead and  sue me)


* think of my past calculations as attempts at uncovering/estimating/coming up with, an estimate of the underlying value of certain assets that are for sale and eventually will be sold (primarily PMX and Dialco). Admittedly I am making estimates without the benefit of all the facts and at best a murky picture of what might be going on behind the scenes.  Call it deductive reasoning (f you are at all a Sherlock fan), mixed with a pinch of financial acumen (mainly borrowed from others around me that are much smarter than I).

As I hope you may have gathered from all your years of being on this board  (although I have my doubts that anything has sunk in based on some of your inane questions of late) , the valuation estimates relate to (an) eventual asset sale(s) to major players in the US market.  Given the now obvious decision by Mgt to forego a US listing, such valuations are not likley to be realized in a material way, in the form of short-term share prices before such sales are inked and announced.  Intermediate time frame value discovery through a rising SP would only happen, IMO, if Spectral were to list on a major US stock exchange . In that event, investors might then be better positioned to anticipate one or more of the eventual sales (and what that will do to the eventual share price).  In other words,  SP discovery (before the ultimate end-game) will only happen if there was:  (1) a much bigger audience, (2) a US lisitng, and (3) lots of PR (including analysts, business channel exposure, etc.).  On the TSX will there be some anticpation?  Likely, but not near what it might be if it traded actively in the US (other than OTC). The audience is (by design IMO) too narrow.  For a while I was convinced that they would take the US Listing route, but that was becasue they said that was their intent. Now I go more by their actions versus their words.

But that doesn't mean that the true or real valuations, or something close to it, won't be achieved in the end-game (ie. via asset sales).

Perhaps I confused you by converting the valuation estimates to a per share figure, using the then o/s & fully diluted share counts?  That only happens on the right exchange with lots of transparancy & PR.  My apologies...but do please try to keep up if you insist on criticizing others.

So if it's an endgame play, then what?  Of course, in the end, it is up to Mgt to do their job and get in front of said major players who are not put off by billion $ price tags, convince them of the value of what Spectral has achieved and is likely to achieve (think FDA) in the short and medium term, negotiate hard, and close a deal.  I believe that this can, and IS, likely happening simultaneous to the completion of  the various FDA milestones (EAA done, SAMI, done, DIMI , partially done, and PMX in a 3B "confirmatory Trial').

Will they get  maximum value on behalf of all shareholders ?  That remains to be seen.

Hope this helps you to at least come down a few branches....so that things seem a little less scary for you.  Focus on the company and thier management does, and don't become overly obsessed about what posters on SH are saying.  I'm pulling for you.  Don't worry, the ladder is coming soon...and a handsome fireman in red suspenders will take you into his arms...and make it all better.

MM
<< Previous
Bullboard Posts
Next >>